Zai Lab Ltd ( (HK:9688) ) just unveiled an announcement.
Zai Lab Limited has announced that its Audit Committee will review and approve the company’s unaudited quarterly results for the first quarter of 2025 on May 8, 2025. The results, prepared in accordance with U.S. GAAP and SEC rules, will be published on the same day. Following the release, the company will host a live earnings call and webcast to discuss the results, providing an opportunity for stakeholders to engage with the company’s management.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands. It focuses on developing and commercializing innovative therapies, primarily in the fields of oncology, autoimmune, and infectious diseases. The company is listed on the Hong Kong Stock Exchange under the stock code 9688.
YTD Price Performance: 8.20%
Average Trading Volume: 400
Technical Sentiment Signal: Sell
Current Market Cap: €3.05B
See more insights into 9688 stock on TipRanks’ Stock Analysis page.